- Home
- AVTX vs HOWL Comparison
AVTX vs HOWL Comparison
Compare AVTX & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- HOWL
- Stock Information
- Founded
- AVTX 2011
- HOWL 2017
- Country
- AVTX United States
- HOWL United States
- Employees
- AVTX N/A
- HOWL N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- HOWL Health Care
- Exchange
- AVTX Nasdaq
- HOWL Nasdaq
- Market Cap
- AVTX 88.4M
- HOWL 62.4M
- IPO Year
- AVTX 2015
- HOWL 2021
- Fundamental
- Price
- AVTX $7.42
- HOWL $1.21
- Analyst Decision
- AVTX Strong Buy
- HOWL Strong Buy
- Analyst Count
- AVTX 5
- HOWL 3
- Target Price
- AVTX $36.75
- HOWL $9.00
- AVG Volume (30 Days)
- AVTX 102.5K
- HOWL 242.3K
- Earning Date
- AVTX 05-12-2025
- HOWL 03-11-2025
- Dividend Yield
- AVTX N/A
- HOWL N/A
- EPS Growth
- AVTX N/A
- HOWL N/A
- EPS
- AVTX N/A
- HOWL N/A
- Revenue
- AVTX $820,000.00
- HOWL $1,885,000.00
- Revenue This Year
- AVTX N/A
- HOWL $36.45
- Revenue Next Year
- AVTX N/A
- HOWL $296.58
- P/E Ratio
- AVTX N/A
- HOWL N/A
- Revenue Growth
- AVTX N/A
- HOWL N/A
- 52 Week Low
- AVTX $4.35
- HOWL $1.03
- 52 Week High
- AVTX $34.46
- HOWL $6.89
- Technical
- Relative Strength Index (RSI)
- AVTX 49.36
- HOWL 40.43
- Support Level
- AVTX $6.38
- HOWL $1.18
- Resistance Level
- AVTX $8.40
- HOWL $1.30
- Average True Range (ATR)
- AVTX 1.11
- HOWL 0.10
- MACD
- AVTX 0.08
- HOWL 0.00
- Stochastic Oscillator
- AVTX 21.93
- HOWL 47.37
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.